Investors have raised bets that the Fed could deliver a 25bp hike as soon as this month, but Federated Hermes chief market strategist Phil Orlando said that is unlikely, expecting the Fed to look through a temporary energy-supply shock and keep rates unchanged. Last week’s weak US labour-market data pushed expectations for a final hike later into the year. London Stock Exchange Group data show money markets price a July 25bp hike at 22%.

Ex-hedge fund manager Jim Cramer said SK Hynix will list on Nasdaq on Friday, calling it a potential opportunity but warning of significant investment risk. He cited continued AI-driven demand for memory as the bullish thesis but flagged the sector’s strong cyclicality and the risk that rising supply could erode returns. Cramer noted the stock trades at only about 7x this year’s expected earnings and recommended establishing a small starter position while keeping cash to buy further on pullbacks. SK Hynix shares are roughly 25% below their June 25 high.

July 8 — AstraZeneca and Ionis launched eplontersen sodium injection (brand name Wanovive) in China. The drug was approved in China in December 2025 for treatment of adults with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).